The system provides ultra-sensitive identification and monitoring at the molecular level of residual disease. Credit: Datar Cancer Genetics / PRNewswire.

Datar Cancer Genetics (DCG) has launched the Target-MRD blood test, designed for the identification and monitoring of molecular residual disease (MRD) in individuals with solid organ cancers.

This test employs a combination of tumour-agnostic next-generation sequencing (NGS) and personalised tumour-informed droplet digital PCR (dd-PCR) assay.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

A small number of tumour cells might remain in the patient’s body after initial anti-cancer treatments, posing a risk of relapse.

Conventional genomic and imaging methods often fail to identify this minimal residual disease. The system aims to fill this gap by providing ultra-sensitive detection, as well as monitoring at the molecular level. This enables the early intervention of oncologists and potentially preventing disease progression, the company noted.

DCG global strategy and medical affairs senior director Dr Darshana Patil said: “Target-MRD reflects DCG’s commitment to safe, reliable and accurate technologies. It is the next-generation test that has the potential not only to detect recurrence earlier but to adapt itself to each patient’s individual requirements and helps to personalise cancer management decisions.

“With its ability to sensitively detect minimal residual disease, Target-MRD empowers clinicians with the information they need to make timely, data-driven decisions, improving patient outcomes and ultimately transforming the way cancer is managed.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Oncology research and applications company DCG is at the forefront of developing non-invasive technologies for identifying, treating, and managing cancer.

The company provides services to individuals suffering from cancer across India, the Gulf Cooperation Council (GCC), the UK, the EU, and the US.

In January 2023, the US Food and Drug Administration (FDA) granted breakthrough device designation to the company’s TriNetra-Glio blood test, which is intended to assist in the diagnosis of inaccessible brain tumours.